Pharmacologic Management of the Opioid Neonatal Abstinence Syndrome

Pediatric Clinics of North America

Volumn 59, Issue 5, 2012, Pages 1147-1165

  Kraft, Walter K ^a   Van den Anker, John N ^b,c,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Clonidine; Neonatal abstinence syndrome; Opioids; Pharmacogenetics; Phenobarbital; Withdrawal

Indexed keywords

BUPRENORPHINE; CLONIDINE; DIAZEPAM; METHADONE; MORPHINE; MU OPIATE RECEPTOR; OPIATE DERIVATIVE; PAREGORIC; PHENOBARBITAL; PLACEBO;

ADJUVANT THERAPY; BRADYCARDIA; BREAST FEEDING; CHILD SAFETY; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HYPOTENSION; IDIOPATHIC DISEASE; LOADING DRUG DOSE; LOW DRUG DOSE; MU OPIATE RECEPTOR 1 GENE; MULTIPLE DRUG ABUSE; MYOCARDITIS; NONHUMAN; OPIATE SUBSTITUTION TREATMENT; OPTIMAL DRUG DOSE; PHARMACOGENETICS; PREDICTION; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; SEIZURE; SINGLE NUCLEOTIDE POLYMORPHISM; SUDDEN INFANT DEATH SYNDROME; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT DURATION; TREATMENT PLANNING; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; FEMALE; HUMANS; INFANT, NEWBORN; NARCOTICS; NEONATAL ABSTINENCE SYNDROME; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84867077990     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2012.07.006     Document Type: Review

References (126)

1. Schneck H. Narcotic withdrawal symptoms in the newborn infant resulting from maternal addiction. J Pediatr 1958, 52:584-587.
2. Dikshit S.K. Narcotic withdrawal syndrome in newborns. Indian J Pediatr 1961, 28:11-15.
3. McCarthy J.E., Siney C., Shaw N.J., et al. Outcome predictors in pregnant opiate and polydrug users. Eur J Pediatr 1999, 158(9):748-749.
4. Swortfiguer D., Cissoko H., Giraudeau B., et al. Neonatal consequences of benzodiazepines used during the last month of pregnancy. Arch Pediatr 2005, 12(9):1327-1331.
5. ACOG Committee on Practice Bulletins-Obstetrics ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists number 92, April 2008. Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008, 111(4):1001-1020.
6. Koren G., Matsui D., Einarson A., et al. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?. CMAJ 2005, 172(11):1457-1459.
7. Law K.L., Stroud L.R., LaGasse L.L., et al. Smoking during pregnancy and newborn neurobehavior. Pediatrics 2003, 111(6 Pt 1):1318-1323.
8. Anand K.J., Willson D.F., Berger J., et al. Tolerance and withdrawal from prolonged opioid use in critically ill children. Pediatrics 2010, 125(5):e1208-e1225.
9. American Academy of Pediatrics Committee on Drugs. Neonatal drug withdrawal. Pediatrics 1998, 101(6):1079-1088.
10. SAMHSA (Substance Abuse, and Mental Health Services Administration) Results from the 2010 national survey on drug use and health: summary of national findings, NSDUH Series H-41 2011, HHS, Rockville, (MD).
11. Finnegan L.P., Kandall S.R. Maternal and neonatal effects of alcohol and drugs 2005, 805-839. Lippincott Williams & Wilkins, Philadelphia. J.H. Lowinson, P. Ruiz, R.B. Millman (Eds.).
12. Kennare R., Heard A., Chan A. Substance use during pregnancy: risk factors and obstetric and perinatal outcomes in South Australia. Aust N Z J Obstet Gynaecol 2005, 45(3):220-225.
13. Kandall S.R., Albin S., Lowinson J., et al. Differential effects of maternal heroin and methadone use on birthweight. Pediatrics 1976, 58(5):681-685.
14. Bell J., Harvey-Dodds L. Pregnancy and injecting drug use. BMJ 2008, 336(7656):1303-1305.
15. Hulse G.K., Milne E., English D.R., et al. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 1997, 92(11):1571-1579.
16. Finnegan L.P., Reeser D.S., Connaughton J.F. The effects of maternal drug dependence on neonatal mortality. Drug Alcohol Depend 1977, 2(2):131-140.
17. Manchikanti L., Fellows B., Ailinani H., et al. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010, 13(5):401-435.
18. Pennsylvania Department of Health. Bureau of Health Statistics & Research Data From The Annual Hospital Questionnaire Reporting Period: July 1, 2008 Through June 30, 2009 Report 14. 2009;2010(10/11):1.
19. Burns L., Mattick R.P. Using population data to examine the prevalence and correlates of neonatal abstinence syndrome. Drug Alcohol Rev 2007, 26(5):487-492.
20. National Pregnancy and Health Survey. NIDA research monograph: Estimated percentage and numbers (in thousands) of infants exposed prenatally to selected substances: Table 4-2. 1996;No. 96-3819:37.
21. Patrick S.W., Schumacher R.E., Benneyworth B.D., et al. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012, 307(18):1934-1940.
22. O'Donnell M., Nassar N., Leonard H., et al. Increasing prevalence of neonatal withdrawal syndrome: population study of maternal factors and child protection involvement. Pediatrics 2009, 123(4):e614-e621.
23. Cleary B.J., Donnelly J., Strawbridge J., et al. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction 2010, 105(12):2071-2084.
24. Jones H.E., Harrow C., O'Grady K.E., et al. Neonatal abstinence scores in opioid-exposed and nonexposed neonates: a blinded comparison. J Opioid Manag 2010, 6(6):409-413.
25. Stine S.M., Heil S.H., Kaltenbach K., et al. Characteristics of opioid-using pregnant women who accept or refuse participation in a clinical trial: screening results from the MOTHER study. Am J Drug Alcohol Abuse 2009, 35(6):429-433.
26. Jansson L.M., Dipietro J.A., Elko A., et al. Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. J Matern Fetal Neonatal Med 2007, 20(9):677-685.
27. Holbrook A., Kaltenbach K. Gender and NAS: does sex matter?. Drug Alcohol Depend 2010, 112(1-2):156-159.
28. Unger A., Jagsch R., Bawert A., et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?. Gend Med 2011, 8(6):355-364.
29. Leeman L.M., Brown S.A., Albright B., et al. Association between intrapartum fetal heart rate patterns and neonatal abstinence syndrome in methadone exposed neonates. J Matern Fetal Neonatal Med 2011, 24(7):955-959.
30. Jansson L.M., Dipietro J.A., Elko A., et al. Infant autonomic functioning and neonatal abstinence syndrome. Drug Alcohol Depend 2010, 109(1-3):198-204.
31. Almario C.V., Seligman N.S., Dysart K.C., et al. Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program. Am J Obstet Gynecol 2009, 201(3):326.e1-326.e6.
32. Cleary B.J., Donnelly J.M., Strawbridge J.D., et al. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol 2011, 204(2):139.e1-139.e9.
33. Liu A.J., Jones M.P., Murray H., et al. Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. Aust N Z J Obstet Gynaecol 2010, 50(3):253-258.
34. Seligman N.S., Salva N., Hayes E.J., et al. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol 2008, 199(4):396.e1-396.e7.
35. Dysart K., Hsieh H.C., Kaltenbach K., et al. Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome. J Perinat Med 2007, 35(4):344-346.
36. Jansson L.M., Di Pietro J.A., Elko A., et al. Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes. Drug Alcohol Depend 2012, 122(3):213-219.
37. Wesson D.R., Smith D.E., Ling W., et al. Sedative-hypnotics. Substance abuse: a comprehensive textbook 2005, 302-312. Lippincott Williams & Wilkins, Philadelphia. 4th edition. J.H. Lowinson, P. Ruiz, R.B. Millman (Eds.).
38. Myllynen P., Vahakangas K. An examination of whether human placental perfusion allows accurate prediction of placental drug transport: studies with diazepam. J Pharmacol Toxicol Methods 2002, 48(3):131-138.
39. McGrath C., Buist A., Norman T.R. Treatment of anxiety during pregnancy: effects of psychotropic drug treatment on the developing fetus. Drug Saf 1999, 20(2):171-186.
40. Wikner B.N., Stiller C.O., Kallen B., et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: maternal characteristics. Pharmacoepidemiol Drug Saf 2007, 16(9):988-994.
41. Czeizel A.E., Eros E., Rockenbauer M., et al. Short-term oral diazepam treatment during pregnancy: a population-based teratological case-control study. Clin Drug Investig 2003, 23(7):451-462.
42. Eros E., Czeizel A.E., Rockenbauer M., et al. A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2002, 101(2):147-154.
43. Dolovich L.R., Addis A., Vaillancourt J.M., et al. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 1998, 317(7162):839-843.
44. Mandelli M., Morselli P.L., Nordio S., et al. Placental transfer to diazepam and its disposition in the newborn. Clin Pharmacol Ther 1975, 17(5):564-572.
45. Iqbal M.M., Sobhan T., Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002, 53(1):39-49.
46. Oei J., Lui K. Management of the newborn infant affected by maternal opiates and other drugs of dependency. J Paediatr Child Health 2007, 43(1-2):9-18.
47. Choo R.E., Huestis M.A., Schroeder J.R., et al. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004, 75(3):253-260.
48. Winklbaur B., Baewert A., Jagsch R., et al. Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers. Implications for treatment. Eur Addict Res 2009, 15(3):150-156.
49. Gray T.R., Choo R.E., Concheiro M., et al. Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome. Addiction 2010, 105(12):2151-2159.
50. Arendt R.E., Short E.J., Singer L.T., et al. Children prenatally exposed to cocaine: developmental outcomes and environmental risks at seven years of age. J Dev Behav Pediatr 2004, 25(2):83-90.
51. Frank D.A., Augustyn M., Knight W.G., et al. Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review. JAMA 2001, 285(12):1613-1625.
52. Schempf A.H. Illicit drug use and neonatal outcomes: a critical review. Obstet Gynecol Surv 2007, 62(11):749-757.
53. Hunt R.W., Tzioumi D., Collins E., et al. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev 2008, 84(1):29-35.
54. Jones H.E., Kaltenbach K., O'Grady K.E. The complexity of examining developmental outcomes of children prenatally exposed to opiates. A response to Hunt et al. Adverse neurodevelopmental outcome of infants exposed to opiates in-utero. Early Human Development (2008, 84, 29-35). Early Hum Dev 2009, 85(4):271-272.
55. Bandstra E.S., Morrow C.E., Mansoor E., et al. Prenatal drug exposure: infant and toddler outcomes. J Addict Dis 2010, 29(2):245-258.
56. Lester B.M., Lagasse L.L. Children of addicted women. J Addict Dis 2010, 29(2):259-276.
57. Kaltenbach K., Finnegan L.P. Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehav Toxicol Teratol 1986, 8(4):353-355.
58. Messinger D.S., Bauer C.R., Das A., et al. The maternal lifestyle study: cognitive, motor, and behavioral outcomes of cocaine-exposed and opiate-exposed infants through three years of age. Pediatrics 2004, 113(6):1677-1685.
59. Farid W.O., Dunlop S.A., Tait R.J., et al. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol 2008, 6(2):125-150.
60. Nandakumar N., Sankar V.S. What is the best evidence based management of neonatal abstinence syndrome?. Arch Dis Child Fetal Neonatal Ed 2006, 91(6):F463.
61. Sarkar S., Donn S.M. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol 2006, 26(1):15-17.
62. O'Grady M.J., Hopewell J., White M.J. Management of neonatal abstinence syndrome: a national survey and review of practice. Arch Dis Child Fetal Neonatal Ed 2009, 94(4):F249-F252.
63. Crocetti M.T., Amin D.D., Jansson L.M. Variability in the evaluation and management of opiate-exposed newborns in Maryland. Clin Pediatr (Phila) 2007, 46(7):632-635.
64. Lipsitz P.J. A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clin Pediatr (Phila) 1975, 14(6):592-594.
65. Green M., Suffet F. The Neonatal Narcotic Withdrawal Index: a device for the improvement of care in the abstinence syndrome. Am J Drug Alcohol Abuse 1981, 8(2):203-213.
66. Zahorodny W., Rom C., Whitney W., et al. The neonatal withdrawal inventory: a simplified score of newborn withdrawal. J Dev Behav Pediatr 1998, 19(2):89-93.
67. Finnegan L.P., Kaltenbach K. Neonatal abstinence syndrome 1992, 1367-1378. Mosby, St Louis (MO). R.A. Hoekelman, S.B. Friedman, N. Nelson (Eds.).
68. Jones H.E., Johnson R.E., Jasinski D.R., et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005, 79(1):1-10.
69. Jones H.E., Kaltenbach K., Heil S.H., et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010, 363(24):2320-2331.
70. Kraft W.K., Dysart K., Greenspan J.S., et al. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction 2011, 106(3):574-580.
71. Agthe A.G., Kim G.R., Mathias K.B., et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics 2009, 123(5):e849-e856.
72. Zimmermann-Baer U., Notzli U., Rentsch K., et al. Finnegan neonatal abstinence scoring system: normal values for first 3 days and weeks 5-6 in non-addicted infants. Addiction 2010, 105(3):524-528.
73. van Sleuwen B.E., Engelberts A.C., Boere-Boonekamp M.M., et al. Swaddling: a systematic review. Pediatrics 2007, 120(4):e1097-e1106.
74. Jansson L.M. Neonatal abstinence syndrome. Acta Paediatr 2008, 97(10):1321-1323.
75. Oei J., Feller J.M., Lui K. Coordinated outpatient care of the narcotic-dependent infant. J Paediatr Child Health 2001, 37(3):266-270.
76. Coyle M.G., Ferguson A., Lagasse L., et al. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr 2002, 140(5):561-564.
77. Osborn D.A., Jeffery H.E., Cole M.J. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2010, (10). CD002059.
78. Osborn D.A., Jeffery H.E., Cole M.J. Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2010, (10). CD002053.
79. Hudak M.L., Tan R.C. Neonatal drug withdrawal. Pediatrics 2012, 129(2):e540-e560.
80. Jansson L.M., Velez M. Neonatal abstinence syndrome. Curr Opin Pediatr 2012, 24(2):252-258.
81. Johnson K., Gerada C., Greenough A. Treatment of neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed 2003, 88(1):F2-F5.
82. Colombini N., Elias R., Busuttil M., et al. Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadone. Pharm World Sci 2008, 30(3):227-234.
83. Jones H.C. Shorter dosing interval of opiate solution shortens hospital stay for methadone babies. Fam Med 1999, 31(5):327-330.
84. Bouwmeester N.J., Hop W.C., van Dijk M., et al. Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. Intensive Care Med 2003, 29(11):2009-2015.
85. Bouwmeester N.J., Anderson B.J., Tibboel D., et al. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth 2004, 92(2):208-217.
86. Barrett D.A., Barker D.P., Rutter N., et al. Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. Br J Clin Pharmacol 1996, 41(6):531-537.
87. Ferrari A., Coccia C.P., Bertolini A., et al. Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res 2004, 50(6):551-559.
88. Yang F., Tong X., McCarver D.G., et al. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn 2006, 33(4):485-518.
89. Madden J.D., Chappel J.N., Zuspan F., et al. Observation and treatment of neonatal narcotic withdrawal. Am J Obstet Gynecol 1977, 127(2):199-201.
90. Lainwala S., Brown E.R., Weinschenk N.P., et al. A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations. Adv Neonatal Care 2005, 5(5):265-272.
91. Backes C.H., Backes C.R., Gardner D., et al. Neonatal abstinence syndrome: transitioning methadone-treated infants from an inpatient to an outpatient setting. J Perinatol 2011, [Epub ahead of print]. 10.1038/jp.2011.114.
92. Gowing L., Ali R., White J.M. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2009, (3). CD002025.
93. Kraft W.K., Gibson E., Dysart K., et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics 2008, 122(3):e601-e607.
94. Kuhlman J.J., Levine B., Johnson R.E., et al. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998, 93(4):549-559.
95. Anagnostis E.A., Sadaka R.E., Sailor L.A., et al. Formulation of buprenorphine for sublingual use in neonates. Journal of Pediatric Pharmacology & Therapeutics 2011, 16(4):281-284.
96. Jackson L., Ting A., McKay S., et al. A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed 2004, 89(4):F300-F304.
97. Pitlick W., Painter M., Pippenger C. Phenobarbital pharmacokinetics in neonates. Clin Pharmacol Ther 1978, 23(3):346-350.
98. Finnegan L.P., Michael H., Leifer B. The use of phenobarbital in treating abstinence in newborns exposed in utero to psychoactive agents. NIDA Res Monogr 1984, 49:329.
99. Wu D, Kraft WK, Ehrlich ME, et al. Sublingual bioavailability of buprenorphine in newborns with neonatal abstinence syndrome-a case study on physiological and developmental changes using SIMCYP. Presented at the American College of Clinical Pharmacology meeting. Philadelphia (PA), 2009. Available at: Accessed August 10, 2012. http://jdc.jefferson.edu/petfp/24/.
100. Xie H.G., Cao Y.J., Gauda E.B., et al. Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. J Clin Pharmacol 2011, 51(4):502-511.
101. Wachman E.M., Brown M.S., Paul J.A., et al. Single nucleotide polymorphisms and variability in severity of neonatal abstinence syndrome. Pediatric Academic Societies 2012.
102. Mass S.B. Supporting breastfeeding in the United States: the Surgeon General's call to action. Curr Opin Obstet Gynecol 2011, 23(6):460-464.
103. Jansson L.M., Choo R., Velez M.L., et al. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics 2008, 121(1):106-114.
104. Abdel-Latif M.E., Pinner J., Clews S., et al. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics 2006, 117(6):e1163-e1169.
105. McQueen K.A., Murphy-Oikonen J., Gerlach K., et al. The impact of infant feeding method on neonatal abstinence scores of methadone-exposed infants. Adv Neonatal Care 2011, 11(4):282-290.
106. Liu A.J., Nanan R. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics 2008, 121(4):869.
107. Grimm D., Pauly E., Poschl J., et al. Buprenorphine and norbuprenorphine concentrations in human breast milk samples determined by liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2005, 27(4):526-530.
108. Marquet P., Chevrel J., Lavignasse P., et al. Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Ther 1997, 62(5):569-571.
109. Ilett K.F., Hackett L.P., Gower S., et al. Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment. Breastfeed Med 2011, [Epub ahead of print].
110. Lindemalm S., Nydert P., Svensson J.O., et al. Transfer of buprenorphine into breast milk and calculation of infant drug dose. J Hum Lact 2009, 25(2):199-205.
111. Johnson R.E., Jones H.E., Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003, 70(Suppl 2):S87-S101.
112. Lejeune C., Aubisson S., Simmat-Durand L., et al. Ann Med Interne (Paris) 2001, 152(Suppl 7):21-27. [in French].
113. Loustauneau A., Auriacombe M., Daulouede J.P., et al. Ann Med Interne (Paris) 2002, 153(Suppl 7). 2S31-2S36 [in French].
114. SAMHSA (Substance Abuse, and Mental Health Services Administration) SAMHSA clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: treatment improvement protocol series, No. 40 2004, USDHHS, Rockville (MD).
115. Skorpen F., Laugsand E.A., Klepstad P., et al. Variable response to opioid treatment: any genetic predictors within sight?. Palliat Med 2008, 22(4):310-327.
116. Troisi A., Frazzetto G., Carola V., et al. Social hedonic capacity is associated with the A118G polymorphism of the mu-opioid receptor gene (OPRM1) in adult healthy volunteers and psychiatric patients. Soc Neurosci 2011, 6(1):88-97.
117. Campa D., Gioia A., Tomei A., et al. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008, 83(4):559-566.
118. Rakvag T.T., Ross J.R., Sato H., et al. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain 2008, 4:64.
119. Tammimaki A.E., Mannisto P.T. Are genetic variants of COMT associated with addiction?. Pharmacogenet Genomics 2010, 20(12):717-741.
120. Gertler R., Brown H.C., Mitchell D.H., et al. Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent) 2001, 14(1):13-21.
121. Oschman A., McCabe T., Kuhn R.J. Dexmedetomidine for opioid and benzodiazepine withdrawal in pediatric patients. Am J Health Syst Pharm 2011, 68(13):1233-1238.
122. Gowing L., Farrell M., Ali R., et al. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2009, (2). CD002024.
123. De Cock R.F., Piana C., Krekels E.H., et al. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 2011, 67(Suppl 1):5-16.
124. Hoder E.L., Leckman J.F., Poulsen J., et al. Clonidine treatment of neonatal narcotic abstinence syndrome. Psychiatry Res 1984, 13(3):243-251.
125. Leikin J.B., Mackendrick W.P., Maloney G.E., et al. Use of clonidine in the prevention and management of neonatal abstinence syndrome. Clin Toxicol (Phila) 2009, 47(6):551-555.
126. Esmaeili A., Keinhorst A.K., Schuster T., et al. Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate. Acta Paediatr 2010, 99(2):209-214.